Compare Meta Platforms Inc (META) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Merck & Co., Inc. — how do they compare? Meta Platforms Inc trades at $643 (market cap $1.64T), while Merck & Co., Inc. trades at $124.51 (market cap $314.90B). The key difference: Meta Platforms Inc is far larger — about 5.2× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.67%). Which is the better fit depends on your goals.
| META | MRK | |
|---|---|---|
Market Cap | $1.64T | $314.90B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $129.52 |
52-Week Low | $525.72 | $77.60 |
Enterprise Value | $1.65T | $358.32B |
Dividend Yield | 0.33% | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META stock trades at $646.01, down 2.79% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $10.44 surpassing expectations of $6.70. Revenue grew to $201.0B in 2025, though net income dipped to $60.5B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $807.17. Recent news highlights the launch of Muse Spark AI and a legal ruling in Massachusetts regarding youth addiction claims.
The outlook for META is favorable, driven by AI innovation and robust financials, but risks include regulatory lawsuits and high capital expenditures. With 79% of analysts rating it a buy and a price target implying 25% upside, the stock presents a growth opportunity, though investors should weigh legal and competitive pressures against its strong market position and profitability.
Merck (MRK) trades at $127.5, down slightly (-0.14%) on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30. The company reported strong earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, supported by earnings momentum, strategic acquisitions, and strong analyst buy ratings (67.57%). Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the pharmaceutical sector. The stock offers a dividend yield with a recent $0.85 per share payment, appealing for income-focused investors amid steady revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
